Covestor’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$0 Sell
51
-34
-40% – ﹤0.01% 2661
2026
Q2
$0 Buy
85
+75
+750% – ﹤0.01% 2713
2026
Q1
$0 Hold
10
– – ﹤0.01% 2592
2025
Q4
$0 Sell
10
-1
-9% – ﹤0.01% 2567
2025
Q3
$0 Sell
11
-55
-83% – ﹤0.01% 2578
2025
Q2
$0 Sell
66
-17
-20% -$100 ﹤0.01% 2545
2025
Q1
$1K Buy
83
+38
+84% +$456 ﹤0.01% 2042
2024
Q4
$1K Buy
45
+39
+650% +$720 ﹤0.01% 2084
2024
Q3
$0 Hold
6
– – ﹤0.01% 2545
2024
Q2
$0 Hold
6
– – ﹤0.01% 2560
2024
Q1
$0 Hold
6
– – ﹤0.01% 2556
2023
Q4
$0 Sell
6
-5
-45% – ﹤0.01% 2496
2023
Q3
$0 Sell
11
-4
-27% – ﹤0.01% 2480
2023
Q2
$0 Sell
15
-3
-17% – ﹤0.01% 2460
2023
Q1
$0 Sell
18
-3
-14% – ﹤0.01% 2381
2022
Q4
$0 Buy
21
+2
+11% – ﹤0.01% 2402
2022
Q3
$0 Buy
19
+8
+73% – ﹤0.01% 2373
2022
Q2
$0 Sell
11
-3
-21% – ﹤0.01% 2191
2022
Q1
$0 Sell
14
-3
-18% – ﹤0.01% 2310
2021
Q4
$0 Hold
17
– – ﹤0.01% 2226

Other funds holding MYGN

Covestor's MYGN Position: Q3 2026 in Review

Covestor reduced its Myriad Genetics (MYGN) stake by 40% in Q3 2026, cutting 34 shares and leaving 51 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Covestor first reported a position in MYGN in Q4 2021 and has held it in 20 quarters since. The position peaked at $1K in Q1 2025. 176 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

  • Covestor held 51 shares of Myriad Genetics worth $0 as of Q3 2026.
  • Covestor sold 34 Myriad Genetics shares in Q3 2026.
  • Myriad Genetics made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2661 holding.
  • Covestor first reported a position in Myriad Genetics in Q4 2021 and has held it in 20 quarters since.
  • Covestor's Myriad Genetics position peaked at $1K in Q1 2025.
  • 176 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.